Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-adrenergic blocking agents in heart failure.

M Batlouni1, D C de Albuquerque

  • 1Instituto Dante Pazzanese de Cardiologia de São Paulo, SP, Brazil.

Arquivos Brasileiros De Cardiologia
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension].

Arquivos brasileiros de cardiologia·1999
Same author

Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia.

European journal of clinical nutrition·1999
Same author

Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.

American heart journal·1997
Same author

[Impact of new knowledge about physiopathology on the treatment of myocardial ischemia].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·1997
Same author

[The oxidative hypothesis of atherosclerosis and the use of antioxidants in coronary disease].

Arquivos brasileiros de cardiologia·1997
Same author

[Multicenter comparative study of felodipine-ER and nifedipine-OROS in the treatment of mild-to-moderate arterial hypertension].

Arquivos brasileiros de cardiologia·1996

Beta-blockers significantly improve outcomes for patients with chronic heart failure (CHF) by counteracting increased cardiac sympathetic drive. These agents reduce mortality, hospitalizations, and improve heart function in systolic ventricular dysfunction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiac dysfunction in heart failure (HF) is a progressive process driven by neurohormonal responses, notably increased cardiac sympathetic drive.
  • Elevated sympathetic drive contributes to myocardial remodeling, functional decline, and poor prognosis in HF patients.
  • Current guidelines recommend combination therapy including beta-blockers for chronic heart failure (CHF) with systolic ventricular dysfunction.

Purpose of the Study:

  • To review the cardiovascular effects of increased sympathetic drive in heart failure.
  • To discuss the role and benefits of beta-adrenoceptor blocking agents in managing chronic heart failure.
  • To provide guidance on the clinical application, precautions, and adverse event management of beta-blockers in HF therapy.

Main Methods:

  • Review of cardiovascular effects of sympathetic drive.

Related Experiment Videos

  • Analysis of pharmacological properties of key beta-blockers (metoprolol, bisoprolol, carvedilol).
  • Evaluation of major clinical trials and clinical practice recommendations for beta-blocker use in heart failure.

    • Main Results:

    • Beta-blockers, combined with standard therapies, offer significant benefits in chronic heart failure (CHF) classes II-IV with systolic dysfunction.
    • Benefits include improved symptoms, functional capacity, cardiac remodeling, left ventricular function, and reduced hospitalizations.
    • These agents decrease overall and sudden cardiac death rates, with efficacy consistent across ischemic/non-ischemic cardiomyopathy, age, gender, and functional class.

    Conclusions:

    • Beta-blockers are crucial in managing chronic heart failure, mitigating the detrimental effects of sympathetic overactivity.
    • Their use is supported by robust clinical trial data demonstrating broad benefits in diverse HF populations.
    • Proper clinical implementation, including precautions and adverse event management, is essential for optimizing patient outcomes.